Hip fractures and pain following proton therapy for management of prostate cancer

Jose Valery, Nancy P. Mendenhall, Romaine C. Nichols, Randal Henderson, Christopher G. Morris, Zhong Su, William M. Mendenhall, Christopher R. Williams, Zuofeng Li, Bradford S. Hoppe

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Proton therapy (PT) for prostate cancer reduces rectal and bladder dose, but increases dose to the femoral necks. We assessed the risk of hip fracture and pain in men treated with PT for prostate cancer. Material and methods. From 2006 to 2008, 382 men were treated for prostate cancer and evaluated at six-month intervals after PT for toxicities at University of Florida Proton Therapy Institute (UFPTI). The WHO Fracture Risk Assessment Tool (FRAX) generated annual hip-fracture risk for the cohort. The WHO FRAX tool was utilized to generate the expected number of patients with hip fractures and the observed-to-expected ratio; confidence intervals and p-value were generated with the mid-P exact test. Univariate analysis of hip pain as a function of several prognostic factors was accomplished with Fisher's exact test. Results. Median follow-up was four years (range, 0.1-5.5 years). Per FRAX, 3.02 patients were expected to develop a hip fracture without PT. Three PT patients actually developed fractures for a rate of 0.21 fractures per 100 person-years of follow-up. There was an observed-expected ratio of 0.99 (p-value not significant). Forty-eight patients (13%) reported new pain in the hip during follow-up; three required prescription analgesics. Conclusion. PT for prostate cancer did not increase hip-fractures in the first four years after PT compared to expected rates in untreated men.

Original languageEnglish (US)
Pages (from-to)486-491
Number of pages6
JournalActa Oncologica
Volume52
Issue number3
DOIs
StatePublished - Apr 1 2013
Externally publishedYes

Fingerprint

Proton Therapy
Hip Fractures
Prostatic Neoplasms
Pain
Hip
Femur Neck
Prescriptions
Analgesics
Urinary Bladder
Confidence Intervals

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Valery, J., Mendenhall, N. P., Nichols, R. C., Henderson, R., Morris, C. G., Su, Z., ... Hoppe, B. S. (2013). Hip fractures and pain following proton therapy for management of prostate cancer. Acta Oncologica, 52(3), 486-491. https://doi.org/10.3109/0284186X.2012.762995

Hip fractures and pain following proton therapy for management of prostate cancer. / Valery, Jose; Mendenhall, Nancy P.; Nichols, Romaine C.; Henderson, Randal; Morris, Christopher G.; Su, Zhong; Mendenhall, William M.; Williams, Christopher R.; Li, Zuofeng; Hoppe, Bradford S.

In: Acta Oncologica, Vol. 52, No. 3, 01.04.2013, p. 486-491.

Research output: Contribution to journalArticle

Valery, J, Mendenhall, NP, Nichols, RC, Henderson, R, Morris, CG, Su, Z, Mendenhall, WM, Williams, CR, Li, Z & Hoppe, BS 2013, 'Hip fractures and pain following proton therapy for management of prostate cancer', Acta Oncologica, vol. 52, no. 3, pp. 486-491. https://doi.org/10.3109/0284186X.2012.762995
Valery, Jose ; Mendenhall, Nancy P. ; Nichols, Romaine C. ; Henderson, Randal ; Morris, Christopher G. ; Su, Zhong ; Mendenhall, William M. ; Williams, Christopher R. ; Li, Zuofeng ; Hoppe, Bradford S. / Hip fractures and pain following proton therapy for management of prostate cancer. In: Acta Oncologica. 2013 ; Vol. 52, No. 3. pp. 486-491.
@article{1eb342bd91db4bc0aaf9a51d4a8d4d09,
title = "Hip fractures and pain following proton therapy for management of prostate cancer",
abstract = "Background. Proton therapy (PT) for prostate cancer reduces rectal and bladder dose, but increases dose to the femoral necks. We assessed the risk of hip fracture and pain in men treated with PT for prostate cancer. Material and methods. From 2006 to 2008, 382 men were treated for prostate cancer and evaluated at six-month intervals after PT for toxicities at University of Florida Proton Therapy Institute (UFPTI). The WHO Fracture Risk Assessment Tool (FRAX) generated annual hip-fracture risk for the cohort. The WHO FRAX tool was utilized to generate the expected number of patients with hip fractures and the observed-to-expected ratio; confidence intervals and p-value were generated with the mid-P exact test. Univariate analysis of hip pain as a function of several prognostic factors was accomplished with Fisher's exact test. Results. Median follow-up was four years (range, 0.1-5.5 years). Per FRAX, 3.02 patients were expected to develop a hip fracture without PT. Three PT patients actually developed fractures for a rate of 0.21 fractures per 100 person-years of follow-up. There was an observed-expected ratio of 0.99 (p-value not significant). Forty-eight patients (13{\%}) reported new pain in the hip during follow-up; three required prescription analgesics. Conclusion. PT for prostate cancer did not increase hip-fractures in the first four years after PT compared to expected rates in untreated men.",
author = "Jose Valery and Mendenhall, {Nancy P.} and Nichols, {Romaine C.} and Randal Henderson and Morris, {Christopher G.} and Zhong Su and Mendenhall, {William M.} and Williams, {Christopher R.} and Zuofeng Li and Hoppe, {Bradford S.}",
year = "2013",
month = "4",
day = "1",
doi = "10.3109/0284186X.2012.762995",
language = "English (US)",
volume = "52",
pages = "486--491",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Hip fractures and pain following proton therapy for management of prostate cancer

AU - Valery, Jose

AU - Mendenhall, Nancy P.

AU - Nichols, Romaine C.

AU - Henderson, Randal

AU - Morris, Christopher G.

AU - Su, Zhong

AU - Mendenhall, William M.

AU - Williams, Christopher R.

AU - Li, Zuofeng

AU - Hoppe, Bradford S.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background. Proton therapy (PT) for prostate cancer reduces rectal and bladder dose, but increases dose to the femoral necks. We assessed the risk of hip fracture and pain in men treated with PT for prostate cancer. Material and methods. From 2006 to 2008, 382 men were treated for prostate cancer and evaluated at six-month intervals after PT for toxicities at University of Florida Proton Therapy Institute (UFPTI). The WHO Fracture Risk Assessment Tool (FRAX) generated annual hip-fracture risk for the cohort. The WHO FRAX tool was utilized to generate the expected number of patients with hip fractures and the observed-to-expected ratio; confidence intervals and p-value were generated with the mid-P exact test. Univariate analysis of hip pain as a function of several prognostic factors was accomplished with Fisher's exact test. Results. Median follow-up was four years (range, 0.1-5.5 years). Per FRAX, 3.02 patients were expected to develop a hip fracture without PT. Three PT patients actually developed fractures for a rate of 0.21 fractures per 100 person-years of follow-up. There was an observed-expected ratio of 0.99 (p-value not significant). Forty-eight patients (13%) reported new pain in the hip during follow-up; three required prescription analgesics. Conclusion. PT for prostate cancer did not increase hip-fractures in the first four years after PT compared to expected rates in untreated men.

AB - Background. Proton therapy (PT) for prostate cancer reduces rectal and bladder dose, but increases dose to the femoral necks. We assessed the risk of hip fracture and pain in men treated with PT for prostate cancer. Material and methods. From 2006 to 2008, 382 men were treated for prostate cancer and evaluated at six-month intervals after PT for toxicities at University of Florida Proton Therapy Institute (UFPTI). The WHO Fracture Risk Assessment Tool (FRAX) generated annual hip-fracture risk for the cohort. The WHO FRAX tool was utilized to generate the expected number of patients with hip fractures and the observed-to-expected ratio; confidence intervals and p-value were generated with the mid-P exact test. Univariate analysis of hip pain as a function of several prognostic factors was accomplished with Fisher's exact test. Results. Median follow-up was four years (range, 0.1-5.5 years). Per FRAX, 3.02 patients were expected to develop a hip fracture without PT. Three PT patients actually developed fractures for a rate of 0.21 fractures per 100 person-years of follow-up. There was an observed-expected ratio of 0.99 (p-value not significant). Forty-eight patients (13%) reported new pain in the hip during follow-up; three required prescription analgesics. Conclusion. PT for prostate cancer did not increase hip-fractures in the first four years after PT compared to expected rates in untreated men.

UR - http://www.scopus.com/inward/record.url?scp=84875176201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875176201&partnerID=8YFLogxK

U2 - 10.3109/0284186X.2012.762995

DO - 10.3109/0284186X.2012.762995

M3 - Article

C2 - 23360340

AN - SCOPUS:84875176201

VL - 52

SP - 486

EP - 491

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 3

ER -